KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial.

Lihua E Budde, Huilai Zhang, Won-Seog Kim, Dai Maruyama, Eduardo M Rego, Lalita Norasetthada, Huangming Hong, Muhit Ozcan, Young-Woo Jeon, Danielle Leão Cordeiro de Farias, Laura Maria Fogliatto, Astrid Pavlovsky, Hideki Goto, Adam J Olszewski, Nikesh Shah, Bei Hu, Shen Yin, Hao Wu, Iris To, Wahib S Ead, Joan Ashby, Martin Janousek, Song Pham, Jue Wang, Antonia Kwan, Connie L Batlevi, Michael C Wei, Jason Westin

J Clin Oncol 43(36) 3799-3811

PMID41037766
PMCIDPMC12711268
DOI10.1200/JCO-25-01957
发表日期2025-10-02
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

PURPOSE: Prognosis for patients with refractory/relapsed large B-cell lymphoma (LBCL) considered ineligible for curative-intent therapy is poor. The combination of mosunetuzumab, a T-cell-engaging bispecific antibody, and polatuzumab vedotin, an antibody-drug conjugate (Mosun-Pola), represents a novel fixed-duration outpatient therapy. METHODS: In the phase III SUNMO trial, patients with refractory/relapsed LBCL who were ineligible for autologous stem-cell transplant were randomly assigned (2:1) to receive Mosun-Pola or rituximab, gemcitabine, and oxaliplatin (R-GemOx). Dual primary end points were centrally assessed overall response rate (ORR) and progression-free survival (PFS). Overall survival was a key secondary end point. RESULTS: A total of 208 patients were randomly assigned to receive Mosun-Pola (n = 138) or R-GemOx (n = 70). At a median follow-up of 23.2 months, the primary analysis of SUNMO demonstrated that the median PFS was significantly longer with Mosun-Pola than with R-GemOx (11.5 months [95% CI, 5.6 to 18] v 3.8 months [95% CI, 2.9 to 4.1]; hazard ratio for progression or death, 0.41 [95% CI, 0.3 to 0.6]; P < .0001). ORR was significantly greater with Mosun-Pola versus R-GemOx (70% v 40%; P < .0001), with complete response rates of 51% and 24%, respectively. In the Mosun-Pola group, the rate of grade ≥2 cytokine release syndrome (CRS) and usage of tocilizumab occurred in <5% of patients and patient-reported outcomes were improved compared with R-GemOx. CONCLUSION: Mosun-Pola demonstrated superior efficacy versus R-GemOx, with significant improvements in both ORR and PFS, and infrequent CRS events with a manageable safety profile.

KM 提取结果

1 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure3 个面板

FIG 2.

FIG 2. Kaplan-Meier estimates of (A) duration of complete response, (B) centrally assessed PFS, and (C) OS in the primary analysis (intent-to-treat population). GemOx, gemcitabine plus oxaliplatin; Mosun, mosunetuzumab; NE, not estimable; OS, overall survival; PFS, progression-free survival; Pola, polatuzumab vedotin; R, rituximab.

A

duration of complete response

FIG 2. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal
查看结果
B

progression-free survival

FIG 2. · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal
查看结果
C

overall survival

FIG 2. · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.FIG 1. CONSORT diagram showing patient disposition. a The most common reasons for patients not meeting eligibility criteria were inadequate hepatic, hematologic, and renal function (n = 15); reason not specified (n = 15); not having an appropriate histology of lymphoma (n = 8); and not having adequate measurable disease (n = 4). All other reasons for screen failure were due to other inclusion and exclusion criteria, reported in less than five screen-failed patients each. GemOx, gemcitabine plus oxaliplatin; Mosun, mosunetuzumab; Pola, polatuzumab vedotin; R, rituximab.
非 KM Figure
FIG 3.FIG 3. Prespecified subgroup analysis of progression-free survival (intent-to-treat population). a Stratified (unstratified HR, 0.43 [95% CI, 0.29 to 0.63]). ABC, activated B-cell–like; COO, cell of origin; DLBCL, diffuse large B-cell lymphoma; FL3b, follicular lymphoma 3b; GCB, germinal center B-cell–like; GemOx, gemcitabine and oxaliplatin; HGBCL, high-grade B-cell lymphoma; HR, hazard ratio; IPI, International Prognostic Index; Mosun, mosunetuzumab; NE, not estimable; NHL, non-Hodgkin lymphoma; Pola, polatuzumab vedotin; R, rituximab; trFL, transformed follicular lymphoma.
非 KM Figure